The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?

Hdl Handle:
http://hdl.handle.net/10147/135433
Title:
The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
Authors:
Duffy, Michael J; Mullooly, Maeve; O'Donovan, Norma; Sukor, Sumainizah; Crown, John; Pierce, Aisling; McGowan, Patricia M
Citation:
Clinical Proteomics. 2011 Jun 09;8(1):9
Issue Date:
9-Jun-2011
URI:
http://hdl.handle.net/10147/135433
Abstract:
Abstract The ADAMs are transmembrane proteins implicated in proteolysis and cell adhesion. Forty gene members of the family have been identified, of which 21 are believed to be functional in humans. As proteases, their main substrates are the ectodomains of other transmembrane proteins. These substrates include precursor forms of growth factors, cytokines, growth factor receptors, cytokine receptors and several different types of adhesion molecules. Although altered expression of specific ADAMs has been implicated in different diseases, their best-documented role is in cancer formation and progression. ADAMs shown to play a role in cancer include ADAM9, ADAM10, ADAM12, ADAM15 and ADAM17. Two of the ADAMs, i.e., ADAM10 and 17 appear to promote cancer progression by releasing HER/EGFR ligands. The released ligands activate HER/EGFR signalling that culminates in increased cell proliferation, migration and survival. Consistent with a causative role in cancer, several ADAMs are emerging as potential cancer biomarkers for aiding cancer diagnosis and predicting patient outcome. Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer.
Item Type:
Journal Article

Full metadata record

DC FieldValue Language
dc.contributor.authorDuffy, Michael J-
dc.contributor.authorMullooly, Maeve-
dc.contributor.authorO'Donovan, Norma-
dc.contributor.authorSukor, Sumainizah-
dc.contributor.authorCrown, John-
dc.contributor.authorPierce, Aisling-
dc.contributor.authorMcGowan, Patricia M-
dc.date.accessioned2011-07-06T09:25:52Z-
dc.date.available2011-07-06T09:25:52Z-
dc.date.issued2011-06-09-
dc.identifierhttp://dx.doi.org/10.1186/1559-0275-8-9-
dc.identifier.citationClinical Proteomics. 2011 Jun 09;8(1):9-
dc.identifier.urihttp://hdl.handle.net/10147/135433-
dc.description.abstractAbstract The ADAMs are transmembrane proteins implicated in proteolysis and cell adhesion. Forty gene members of the family have been identified, of which 21 are believed to be functional in humans. As proteases, their main substrates are the ectodomains of other transmembrane proteins. These substrates include precursor forms of growth factors, cytokines, growth factor receptors, cytokine receptors and several different types of adhesion molecules. Although altered expression of specific ADAMs has been implicated in different diseases, their best-documented role is in cancer formation and progression. ADAMs shown to play a role in cancer include ADAM9, ADAM10, ADAM12, ADAM15 and ADAM17. Two of the ADAMs, i.e., ADAM10 and 17 appear to promote cancer progression by releasing HER/EGFR ligands. The released ligands activate HER/EGFR signalling that culminates in increased cell proliferation, migration and survival. Consistent with a causative role in cancer, several ADAMs are emerging as potential cancer biomarkers for aiding cancer diagnosis and predicting patient outcome. Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer.-
dc.titleThe ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?-
dc.typeJournal Article-
dc.language.rfc3066en-
dc.rights.holderDuffy et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2011-06-30T12:04:34Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.